Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 6
1963 3
1969 1
1970 2
1971 13
1972 72
1973 76
1974 122
1975 133
1976 148
1977 128
1978 85
1979 110
1980 104
1981 109
1982 118
1983 97
1984 124
1985 156
1986 160
1987 139
1988 193
1989 202
1990 200
1991 201
1992 199
1993 152
1994 197
1995 181
1996 183
1997 154
1998 162
1999 166
2000 201
2001 169
2002 164
2003 207
2004 219
2005 258
2006 328
2007 379
2008 366
2009 379
2010 389
2011 449
2012 518
2013 516
2014 583
2015 559
2016 583
2017 647
2018 713
2019 718
2020 806
2021 751
2022 776
2023 457
2024 511
2025 38

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,286 results

Results by year

Filters applied: . Clear all
Page 1
Streptozocin (Zanosar).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 1982 Nov 12;24(622):100-1. Med Lett Drugs Ther. 1982. PMID: 6290862 Clinical Trial. No abstract available.
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.
Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Moertel CG, et al. N Engl J Med. 1992 Feb 20;326(8):519-23. doi: 10.1056/NEJM199202203260804. N Engl J Med. 1992. PMID: 1310159 Free article. Clinical Trial.
BACKGROUND: The combination of streptozocin and fluorouracil has become the standard therapy for advanced islet-cell carcinoma. ...Chlorozotocin alone is similar in efficacy to streptozocin plus fluorouracil, but it produces fewer gastrointestinal side effects than …
BACKGROUND: The combination of streptozocin and fluorouracil has become the standard therapy for advanced islet-cell carcinoma. ...Ch …
Nephrotoxicity of streptozocin.
Perry DJ, Weiss RB. Perry DJ, et al. Ann Intern Med. 1982 Jan;96(1):122. doi: 10.7326/0003-4819-96-1-122_1. Ann Intern Med. 1982. PMID: 6459048 No abstract available.
Chlorozotocin.
[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risks Hum. 1990;50:65-75. IARC Monogr Eval Carcinog Risks Hum. 1990. PMID: 2149865 Free PMC article. Review. No abstract available.
Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.
Krug S, Boch M, Daniel H, Nimphius W, Müller D, Michl P, Rinke A, Gress TM. Krug S, et al. PLoS One. 2015 Dec 2;10(12):e0143822. doi: 10.1371/journal.pone.0143822. eCollection 2015. PLoS One. 2015. PMID: 26630134 Free PMC article.
BACKGROUND AND AIM: Chemotherapy with streptozocin (STZ) in combination with 5-FU or doxorubicin (Dox) represents a standard of care for patients with metastatic pancreatic neuroendocrine neoplasms (pNEN). ...
BACKGROUND AND AIM: Chemotherapy with streptozocin (STZ) in combination with 5-FU or doxorubicin (Dox) represents a standard of care …
[Streptozotocin].
Rudas B. Rudas B. Arzneimittelforschung. 1972 May;22(5):830-61. Arzneimittelforschung. 1972. PMID: 4340253 Review. German. No abstract available.
Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.
Khan TS, Imam H, Juhlin C, Skogseid B, Gröndal S, Tibblin S, Wilander E, Oberg K, Eriksson B. Khan TS, et al. Ann Oncol. 2000 Oct;11(10):1281-7. doi: 10.1023/a:1008377915129. Ann Oncol. 2000. PMID: 11106117 Free article. Clinical Trial.
BACKGROUND: To evaluate the efficacy of streptozocin and o.p'DDD (SO) in adrenocortical cancer (ACC) patients since other chemotherapeutic regimens have limited effects. ...Oral o,p'DDD administration (1-4 g/d, every day) was given together with intravenous streptozocin …
BACKGROUND: To evaluate the efficacy of streptozocin and o.p'DDD (SO) in adrenocortical cancer (ACC) patients since other chemotherap …
Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.
Moertel CG, Hanley JA, Johnson LA. Moertel CG, et al. N Engl J Med. 1980 Nov 20;303(21):1189-94. doi: 10.1056/NEJM198011203032101. N Engl J Med. 1980. PMID: 6252466 Clinical Trial.
To evaluate the treatment of advanced islet-cell carcinoma, we randomly assigned 84 patients to streptozocin alone or streptozocin plus fluorouracil. Each regimen was given in five-day courses. ...In spite of gastrointestinal side effects, streptozocin combin …
To evaluate the treatment of advanced islet-cell carcinoma, we randomly assigned 84 patients to streptozocin alone or streptozocin …
Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study.
Legoux JL, Lombard-Bohas C, Brixi H, Le Malicot K, Lecomte T, Dahan L, Ruszniewski P, Mahamat-Abakar A, Etienne PL, Caroli-Bosc FX, Dominguez S, Paule B, Terrebonne E, Michel P, Lepage C, Choukroun G; for Streptotox-FFCD0906 investigators. Legoux JL, et al. Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101572. doi: 10.1016/j.clinre.2020.10.014. Epub 2021 Mar 19. Clin Res Hepatol Gastroenterol. 2021. PMID: 33751987 Free article.
INTRODUCTION: Streptozocin can impair renal function. The purpose of this study was to evaluate the evolution of renal function in patients receiving this anti-mitotic for the treatment of locally advanced/metastatic digestive well differentiated neuroendocrine tumours. .. …
INTRODUCTION: Streptozocin can impair renal function. The purpose of this study was to evaluate the evolution of renal function in pa …
14,286 results
You have reached the last available page of results. Please see the User Guide for more information.